Novo Nordisk Pays $60M To End Probe Into Drug Marketing
Novo Nordisk Inc. has agreed to pay at least $60 million to end a federal investigation into its marketing practices and resolve seven whistleblower suits alleging the pharmaceutical company misled physicians...To view the full article, register now.
Already a subscriber? Click here to view full article